Gerhard Bauer, B.S., is an assistant professor of hematology and oncology and director of the Good Manufacturing Practice (GMP) laboratory at the UC Davis Institute for Regenerative Cures. In addition to GMP design and construction expertise, Bauer also has extensive experience in the field of gene and cell therapy, having spent two decades developing novel clinical applications to improve medical outcomes for life-threatening illnesses.
David Segal, Ph.D., is a professor of biochemistry and molecular medicine at UC Davis and works in the Genome Center. His research interests include molecular therapy for neurologic genetic diseases, epigenetics of non-genetic mental illness, determinants of epigenetic persistence and addressing the challenges for gene editing in the clinic.
Jason Lambert, Ph.D., is a postdoctoral researcher at the UC Davis Center for Neuroscience as well as a lecturer at California State University, Sacramento. In his postdoctoral work, he is studying how non-coding sequences impact neurodevelopment and developing new tools to detect sequences in the genome that have transcriptional enhancer activity.
Kyle Fink, Ph.D., is an assistant professor at the UC Davis Neurology and Institute for Regenerative Cures. His research team focuses on genetically-linked neurological disorders such as CDKL5 deficiency (rare intractable pediatric epilepsy), Angelman’s Syndrome, and Huntington’s disease that are targetable with gene editing molecules in addition to some forms of brain cancer.